DexCom, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request metadata identifies 2023 Q4, this filing reports annual results; the supplied filing text does not provide standalone fourth-quarter financial results.
Business context
DexCom designs, develops, and sells continuous glucose monitoring (CGM) systems for diabetes management. Its principal products include the G6 and G7; G7 received U.S. FDA clearance in December 2022. DexCom reported one global business segment. Disposable sensors and other revenue represented about 90% of FY2023 revenue, with reusable hardware about 10%. The United States generated 72% of revenue and international markets 28%; distributors accounted for 85% of revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $3.622 billion | $2.910 billion | +24% |
| Gross profit / margin | $2.289 billion / 63.2% | $1.883 billion / 64.7% | Profit +22%; margin down 1.5 percentage points |
| Operating income / margin | $597.7 million / about 16.5% | $391.2 million / about 13.4% | +53% |
| Net income / diluted EPS | $541.5 million / $1.30 | $341.2 million / $0.82 | Net income +59% |
| Cash from operations | $748.5 million | $669.5 million | +12% |
| Capital expenditures | $236.6 million | $364.8 million | Down $128.2 million |
Operating cash flow less reported capital expenditures was approximately $511.9 million in FY2023; this is a simple calculation, not a company-reported non-GAAP measure. Revenue growth was primarily driven by higher sensor sales and a growing worldwide customer base, partly offset by product and channel mix and pricing. Gross margin declined mainly due to higher intangible-asset amortization and price, product, and channel mix. SG&A rose 18%, including higher compensation, patent-litigation expense, and global product-launch marketing.
At year-end, cash, cash equivalents, and short-term marketable securities totaled $2.72 billion. The company reported a 2.84 working-capital ratio and 2.38 quick ratio. Convertible-note principal totaled $2.458 billion, with $2.434 billion carrying value; notes mature in November 2025 and May 2028. The $200 million revolving facility had no borrowings, $7.4 million of letters of credit, and $192.6 million available. DexCom said cash, investments, expected operating cash flows, and available borrowing capacity should cover anticipated requirements for at least 12 months.
Material changes, outlook, and risks
- FY2023 revenue and earnings increased substantially year over year, while gross margin eased. Interest and dividend income rose to $135.0 million from $23.8 million, contributing to other income of $112.7 million versus a slight expense in FY2022.
- Operating cash flow increased, but higher inventory and receivables absorbed cash. Inventory was $559.6 million at year-end, up from $306.7 million; accounts receivable was $973.9 million, up from $713.3 million.
- Manufacturing expansion is underway: DexCom began commercial manufacturing at its new Malaysia facility, is expanding Mesa, Arizona capacity, and plans an Ireland facility. Management expects significant related capital expenditures, including in the coming year.
- No quantified FY2024 revenue or earnings guidance is provided in the supplied text. Management expects positive operating cash flow to continue and says available liquidity is expected to fund core operations and planned needs.
- Dexcom Stelo, designed for people with type 2 diabetes who do not use insulin and are not at hypoglycemia risk, was submitted to the FDA in Q4 2023. Regulatory timing and commercialization remain uncertain.
- Key risks include reimbursement and pricing pressure, competition, manufacturing scale-up and single-source suppliers, product quality and liability, regulatory approvals, cybersecurity and privacy compliance, foreign-exchange exposure, and reliance on distributors. DexCom disclosed that certain distributor relationships each generated at least 10% of revenue.
- DexCom and Abbott are engaged in patent litigation in multiple jurisdictions, seeking damages and injunctive relief. The company said it could not reasonably estimate the ultimate outcome. It also reported a 2023 jury verdict on aspects of the parties’ settlement-agreement dispute and mixed patent-review outcomes; litigation continues.
- Unusual financial items include a 2023 intra-entity intellectual-property transfer that contributed to tax expense, a $185.5 million increase in the deferred-tax valuation allowance, and $38.6 million of intangible amortization versus $11.8 million in FY2022. The first Verily sales-based milestone was met and paid in 3.7 million shares.
- DexCom repurchased $500 million of stock under its 2023 accelerated repurchase program. The financial statements received an unqualified audit opinion; management and the auditor reported effective internal control over financial reporting at December 31, 2023.
Investor verification priorities
- Obtain the quarterly financial statements or earnings release to confirm Q4 revenue, margins, cash flow, and any quarter-specific items; the annual filing text here does not give standalone Q4 figures.
- Track G7 adoption, sensor-versus-hardware mix, pricing and rebate trends, and the effect of payer coverage on sales and gross margin.
- Assess manufacturing capacity, yields, quality, supplier continuity, and the timing and cost of the Malaysia, Mesa, and planned Ireland expansions.
- Review the Abbott litigation docket and potential financial, product, or market-access consequences; the filing does not quantify a likely loss.
- Monitor convertible-note maturity and conversion terms, potential dilution, and the company’s ability to fund capital spending and debt obligations while maintaining liquidity.
- Check FDA progress for Stelo and other product indications, alongside evolving reimbursement, privacy, and cybersecurity requirements.